Effectiveness and safety of atomoxetine for ADHD in population between 6 and 19 years: a systematic review

• Main Authors: José Calleja, José Uribarr
• Format: Article
• Language: English
• Published: Medwave Estudios Limitada 2012-09-01
• Series: Medwave
• Subjects: attention deficit disorder with hyperactivity; atomoxetine; systematic review
• Online Access: http://dx.doi.org/10.5867/medwave.2012.08.5471

Introduction: Attention deficit hyperactivity disorder (ADHD) is generally treated with pharmacological interventions such as psychostimulants. The most used widely used one is methylphenidate followed by atomoxetine. Purpose: To identify, synthesize and evaluate the best available evidence on the effectiveness and safety of atomoxetine in ADHD treatment in the 6-19 year-old population. Methods: A systematic review of intervention studies that evaluated effectiveness of atomoxetine compared with placebo and methylphenidate was conducted. Outcomes assessed were educational functioning, psychosocial functioning, quality of life and adverse effects. The search was done up to February 2012 in English and Spanish in the following databases: PubMed/MEDLINE, LILACS, Cochrane, DARE and National Guideline Clearinghouse. The articles were independently evaluated by two investigators. Results: Of the 108 studies found initially, 11 were included, among which five systematic reviews, one primary article and 5 clinical guidelines. Conclusions: Atomoxetine is recommended as a second option in ADHD and was found to be superior to placebo. Its use is recommended when methylphenidate fails or comorbidities are present.